The FDA grants Priority Review to brepocitinib for dermatomyositis after trial results show significant muscle and skin improvements in patients.

In the phase 3 VERIFY trial, rusfertide was associated with a significantly higher proportion of patients achieving clinical response compared with placebo.

Lomitapide is a microsomal triglyceride transfer protein inhibitor designed to inhibit the formation of chylomicrons and very low-density lipoprotein.

Incidence rates increased by 3% annually among adults aged 20 to 49 years and by 0.4% annually for those aged 50 to 64 years.

Nipocalimab, an FcRn blocker, receives FDA Fast Track status for SLE treatment after demonstrating significant improvements in disease activity.

HealthDay News — The prevalence of obesity and severe obesity markedly increased among adults and children in the US from the 1970s and 1980s until now, according to two reports published in the ...

Since the 1990s, the FDA has collected fees from drug companies to help pay for stepped-up staffing enable faster reviews of new prescription drugs and vaccines. In turn, the agency must meet certain ...

This once-weekly C-type natriuretic peptide analog functions by antagonizing overactive FGFR3 signaling to improve growth in pediatric patients.

Prevalence of hypertension, diabetes, and obesity estimated to increase, while hypercholesterolemia set to decline ...

Treatment with fenebrutinib significantly reduced the annualized relapse rate by 51% compared with teriflunomide. Topline data were announced from a second phase 3 trial evaluating fenebrutinib, an ...

Review reveals refusal tied to significantly higher risk for life-threatening brain bleeds and long-term neurological disability.

Long-term morbidity varies by chemotherapy regimen, with higher odds of worse renal impairment seen with EPx4 vs BEPx3.